Merck Patent Gesellschaft MIT Beschrankter Haftung

Merck Patent Gesellschaft

Mathias Osswald

Dieter Dorsch

Werner Mederski

Maria Christadler

Claus J Schmitges

Claudia Wilm

Norbert Beier

Klaus-Otto Minck

Pierre Schelling

Ingeborg Lues

Andreas Bathe

Soheila Anzali

Thorsten Hartig

Benzothia(oxa)diazol derivatives and their use as endothelin-receptor antagonists

2,1,3-benzothia(OXA)diazole derivatives having an endothelin receptor

Endothelin receptor antagonists

Novel compounds of the formula I ##STR1## in which R.sup.1, R.sup.2, R.sup.3 and X have the meaning indicated in claim 1, and their salts exhibit endothelin receptor-antagonistic properties.

Novel compounds of the formula I ##STR1## in which --Y--Z--, R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 have the meanings as stated in the specification, and their salts show endothelin receptor antagonist properties.

Novel compounds of the formula I ##STR1## in which R.sup.1, R.sup.2, R.sup.3, --A.dbd.B--C.dbd.D--, Ar and X have the meaning indicated in claim 1, and their salts show endothelin receptor-antagonistic properties.

Novel compounds of the formula ##STR1## in which --Y--Z--, R.sup.1 R.sup.2, R.sup.3, R.sup.4, R.sup.5 and X have the meaning indicated and their salts show endothelin receptor-antagonistic properties.

Novel imidazopyridine derivatives of the formula ##STR1## wherein R is ##STR2## and R.sup.1, R.sup.2, R.sup.3, R.sup.4, Ar.sup.1, X and Y are as defined in the specification, and their salts, exhibit antagonistic properties toward angiotensin II and can be used for the treatment of hypertension, aldosteronism, cardiac insufficiency and increased intraocular pressure, and of disorders of the central nervous system.

Imidazopyridines

Novel imidazopyridine derivatives of formula I: ##STR1## wherein R is ##STR2## and R.sup.1, R.sup.2, R.sup.3, R.sup.4, X and Y are as defined herein, and their salts, exhibit antagonistic properties toward angiotensin II and can be used for the treatment of hypertension, aldosteronism, cardiac insufficiency and increased intraocular pressure, and of disorders of the central nervous system.

Novel imidazopyridine derivatives of formula I ##STR1## wherein ##STR2## and R.sup.1, R.sup.2, R.sup.3, R.sup.4, X and Y are as defined herein, and their salts, exhibit antagonistic properties toward angiotensin II and can be used for the treatment of hypertension, aldosteronism, cardiac insufficiency and increased intraocular pressure, and of disorders of the central nervous system.

Imidazopyridines as angiotensin II antagonists

Novel imidazopyridine derivatives of formula I ##STR1## and X, --Y.dbd.Z--, R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 as defined herein, and their salts, exhibit antagonistic properties towards angiotensin II and can be used for the treatment of hypertension, aldosteronism, cardiac insufficiency and increased intraocular pressure, and of disorders of the central nervous system.

Benzimidazole compounds of the formula I ##STR1## and salts thereof, exhibit antagonistic properties toward angiotensin II and can be used for the treatment of hypertension, aldosteronism, cardiac insufficiency and an increased intraocular pressure, as well as disturbances of the central nervous system.

Benzimidazole compounds

Novel imidazopyridine derivatives of the formula I ##STR1## in which R is ##STR2## and R.sup.1 to R.sup.4, X and Y are as defined herein, and their salts have antagonistic properties towards angiotensin(II) and can be used for the treatment of hypertension, aldosteronism, cardiac insufficiency and increased intraocular pressure and also disorders of the central nervous system.

Growing community of inventors

Zwingenberg, Germany

Mathias Osswald